ASPET Journals Support the National Institutes of Health Principles and Guidelines for Reporting Preclinical Research

摘要

Over the last several years there has been growing concern within the biomedical research community regarding a common perception that the level of scientific reproducibility and self-correction in preclinical research is not adequate (Collins and Tabak, 2014). In one initiative to address this situation, the National Institutes of Health (NIH) in collaboration with Nature and Science/American Association for the Advancement of Science held a workshop on June 14, 2014, for biomedical journal editors (including The Journal of Pharmacology and Experimental Therapeutics) that addressed the reproducibility and rigor of published research findings. Workshop attendees provided input to a draft set of methodological guidelines for published research. The ASPET Board of Publications Trustees reviewed the draft guidelines and submitted a response to the NIH on August 19, 2014. On November 5, 2014, the National Institutes of Health announced "Principles and Guidelines for Reporting Preclinical Research" (http://www.nih.gov/about/reporting-pre-clinical-research.htm). The guidelines address five principle areas of concern for the publication of preclinical biological research: rigorous statistical analysis, transparency in reporting, data and material sharing, consideration of refutations, and the establishment of best practice guidelines in the areas of image-based data and the description of biological materials with enough information to uniquely identify the reagents (in particular, antibodies, cell lines, and animals). ASPET publishes three primary research journals: The Journal of Pharmacology and Experimental Therapeutics (JPET; founded in 1909), Molecular Pharmacology (1965), and Drug Metabolism and Disposition (DMD; 1973). ASPET also publishes a review journal, Pharmacological Reviews, established in 1949. It is the intent and mission of ASPET's journals to hold to high standards of scientific rigor.